Your browser doesn't support javascript.
loading
Breakthrough infections with the omicron and delta variants of SARS-CoV-2 result in similar re-activation of vaccine-induced immunity.
Søraas, Arne; Grødeland, Gunnveig; Granerud, Beathe Kiland; Ueland, Thor; Lind, Andreas; Fevang, Børre; Murphy, Sarah L; Huse, Camilla; Nygaard, Anders Benteson; Steffensen, Anne Katrine; Al-Baldawi, Huda; Holberg-Petersen, Mona; Andresen, Lise Lima; Ågnes, Camilla; Ranheim, Trine; Schanke, Ylva; Istre, Mette; Dahl, John Arne; Chopra, Adity; Dudman, Susanne; Kaarbø, Mari; Andersen, Jan Terje; Vaage, Eline Benno; Tran, Trung The; Vaage, John Torgils; Michelsen, Annika E; Müller, Fredrik; Aukrust, Pål; Halvorsen, Bente; Dahl, Tuva B; Holter, Jan Cato; Lund-Johansen, Fridtjof.
  • Søraas A; Department of Microbiology, Oslo University Hospital, Oslo, Norway.
  • Grødeland G; Department of Immunology, Oslo University Hospital, Oslo, Norway.
  • Granerud BK; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Ueland T; Department of Microbiology, Oslo University Hospital, Oslo, Norway.
  • Lind A; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Fevang B; Department of Nursing, Health and Laboratory Science, University College of Østfold, Fredrikstad, Norway.
  • Murphy SL; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Huse C; Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.
  • Nygaard AB; Faculty of Health Sciences, K.G. Jebsen Thrombosis Research and Expertise Center, University of Tromsø, Tromsø, Norway.
  • Steffensen AK; Department of Microbiology, Oslo University Hospital, Oslo, Norway.
  • Al-Baldawi H; Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.
  • Holberg-Petersen M; Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Oslo, Norway.
  • Andresen LL; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Ågnes C; Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.
  • Ranheim T; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Schanke Y; Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.
  • Istre M; Department of Microbiology, Oslo University Hospital, Oslo, Norway.
  • Dahl JA; Department of Microbiology, Oslo University Hospital, Oslo, Norway.
  • Chopra A; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Dudman S; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Kaarbø M; Department of Microbiology, Oslo University Hospital, Oslo, Norway.
  • Andersen JT; Department of Microbiology, Oslo University Hospital, Oslo, Norway.
  • Vaage EB; Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.
  • Tran TT; Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.
  • Vaage JT; Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.
  • Michelsen AE; Department of Microbiology, Oslo University Hospital, Oslo, Norway.
  • Müller F; Department of Microbiology, Oslo University Hospital, Oslo, Norway.
  • Aukrust P; Department of Immunology, Oslo University Hospital, Oslo, Norway.
  • Halvorsen B; Department of Microbiology, Oslo University Hospital, Oslo, Norway.
  • Dahl TB; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Holter JC; Department of Microbiology, Oslo University Hospital, Oslo, Norway.
  • Lund-Johansen F; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Front Immunol ; 13: 964525, 2022.
Article en En | MEDLINE | ID: mdl-36159859
Background: Results showing that sera from double vaccinated individuals have minimal neutralizing activity against Omicron have been interpreted as indicating the need for a third vaccine dose for protection. However, there is little information about early immune responses to Omicron infection in double vaccinated individuals. Methods: We measured inflammatory mediators, antibodies to the SARS-CoV-2 spike and nucleocapsid proteins, and spike peptide-induced release of interferon gamma in whole blood in 51 double-vaccinated individuals infected with Omicron, in 14 infected with Delta, and in 18 healthy controls. The median time points for the first and second samples were 7 and 14 days after symptom onset, respectively. Findings: Infection with Omicron or Delta led to a rapid and similar increase in antibodies to the receptor-binding domain (RBD) of Omicron protein and spike peptide-induced interferon gamma in whole blood. Both the Omicron- and the Delta-infected patients had a mild and transient increase in inflammatory parameters. Interpretation: The results suggest that two vaccine doses are sufficient to mount a rapid and potent immune response upon infection in healthy individuals of with the Omicron variant. Funding: The study was funded by the Oslo University Hospital, and by grants from The Coalition for Epidemic Preparedness Innovations, Research Council of Norway (no 312780, 324272), South-Eastern Norway Regional Health Authority (no 2019067, 2021071, 10357, 2021047, 33612, 2021087, 2017092), EU Horizon 2020 grant no 848099, a philantropic donation from Vivaldi Invest A/S, and The European Virus Archive Global.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas Virales / COVID-19 Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas Virales / COVID-19 Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article